The first-of-its kind clinical trial was presented at the 2024 ASTRO Annual Meeting. The study investigators say the 5-year survival rate "dramatically exceeds historical standards." A long-term study points to the importance of evaluating risks and benefits with estrogen versus progesterone with estrogen. Patients receiving the antibody-drug conjugate showed a 30% reduction in the risk of death compared with chemotherapy. A new study is shedding light on post-treatment experiences, with many saying they felt they were "left to themselves." Oncology nurses can play a key role in improving outcomes and quality of life for patients with metastatic pancreatic cancer. An interim analysis of part 2 of the RUBY trial showed that dostarlimab plus chemotherapy lowered the risk of death by 31%. Learn what a team of researchers found about the impact of this practice. Dr. Bose shared his insights at the Twelfth Annual Society of Hematologic Oncology Meeting in Houston. A new study highlights the importance of effective management and close monitoring of GVHD. It's critical for oncology nurses understand and recognize the 3 atypical lung cGVHD conditions. A small study evaluated the ROCK2 inhibitor for treatment of ocular GVHD because corneal epithelial cells express ROCK2. Researchers explored the relationship between post-traumatic growth and perceived stress in this population of patients. The expanded approval is based upon results from part 1 of the phase III RUBY trial. More than half of patients did not receive palliative care, but among those who did, 36% received it late. The approval is supported by data from the phase III PERSEUS study. The trial is the first to evaluate the combination of an ADC and a TKI in metastatic urothelial carcinoma. Vimseltinib demonstrated “clinically meaningful functional and symptomatic improvement" in patients with TGCT. This form of the drug does not require reconstitution or dilution and can be administered directly from the vial. DSP-5336 is an investigational small-molecule inhibitor of the menin and MLL protein interaction.